Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism

References

• Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs64(14), 1575–1596 (2004).
   Google Scholar
• Keam SJ, Goa KL. Fondaparinux sodium. Drugs62(11), 1673–1685 (2002); discussion 62(11), 1686–1677 (2002).
   Google Scholar
• Cheng JW. Fondaparinux: a new antithrombotic agent. Clin. Ther.24(11), 1757–1769; discussion 1719 (2002).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin. Investig. Drugs14(7), 847–858 (2005).
   PubMed Web of Science ®Google Scholar
• Alban S. From heparins to Factor Xa inhibitors and beyond. Eur. J. Clin. Invest.35(Suppl.1), 12–20 (2005).
   PubMed Web of Science ®Google Scholar
• Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res.109(1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Samama MM. Heterogeneity of synthetic Factor Xa inhibitors. Curr. Pharm. Des.11(30), 3855–3876 (2005).
   Google Scholar
• Hawkins D. Clinical trials with Factor Xa inhibition in the prevention of postoperative venous thromboembolism. Am. J. Health Syst. Pharm.60(22 Suppl. 7), S6–S10 (2003).
   Google Scholar
• Gerotziafas GT, Depasse F, Chakroun T et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul. Fibrinolysis15(2), 149–156 (2004).
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb. Haemost.92(6), 1296–1302 (2004).
   Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban. J. Thromb. Haemost.5(4), 886–888 (2007).
   PubMed Web of Science ®Google Scholar
• Pengo V. New trends in anticoagulant treatments. Lupus14(9), 789–793 (2005).
   Google Scholar
• Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med.344(9), 619–625 (2001).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med.345(18), 1298–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet359(9319), 1721–1726 (2002).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet359(9319), 1715–1720 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Bauer KA, Eriksson BL, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery – a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162(16), 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med.345(18), 1305–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery – a multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med.163(11), 1337–1342 (2003).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg.92(10), 1212–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Bauer KA, Caprini JA et al. Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of venous thromboembolism after major abdominal surgery: the randomized APOLLO Study. ASH Annual Meeting Abstracts106(11), (2005) (Abstract 279).
   Google Scholar
• The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-Factor Xa activity: a Phase II evaluation. Circulation102(22), 2726–2731 (2000).
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med.140(11), 867–873 (2004).
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med.349(18), 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Coussement PK, Bassand JP, Convens C et al. A synthetic Factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction – The PENTALYSE study. Eur. Heart J.22(18), 1716–1724 (2001).
   PubMed Web of Science ®Google Scholar
• Simoons ML, Bobbink IWG, Boland J et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol.43(12), 2183–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Steg PG, Granger CB et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention – Arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial. Circulation111(11), 1390–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med.354(14), 1464–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA295(13), 1519–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Davidson BL, Gallus AS et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br. Med. J.332(7537), 325–329 (2006).
   PubMed Web of Science ®Google Scholar
• Savi P, Chong BH, Greinacher A et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood105(1), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy27(4), 564–587 (2007).
   PubMedGoogle Scholar
• Warkentin TE, Cook RJ, Marder VJ et al. Anti-platelet Factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood106(12), 3791–3796 (2005).
   PubMed Web of Science ®Google Scholar
• Dager WE, Andersen J, Nutescu E. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy24(7 Pt 2), S88–S94 (2004).
   Google Scholar
• Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med.349(18), 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Contributed Poster Presentations. Value Health6(6), 635–809 (2003).
   Google Scholar
• Stumpo C, Kahn S, Martineau J et al. Pharmacoeconomic analysis of fondaparinux for the prevention of thromboembolic events in orthopedic surgical patients. Can. J. Hosp. Pharm.56(Suppl. 3), 29 (2003).
   Google Scholar
• Annemans L DK. Annemans L, DeGroot K. Cost–effectiveness of fondaparinux (Arixtra) compared with enoxaparin as prophylaxis against venous thromboembolism following major orthopedic surgery. J. Thromb. Haemost.1(Suppl. 1), (2003) (Abstract 2053).
   Google Scholar
• Gordois A, Posnett J, Borris L et al. The cost–effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost.1(10), 2167–2174 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Davidson BL, Kahn SR et al. A cost–effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism – use in patients undergoing major orthopaedic surgery. Pharmacoeconomics22(9), 605–620 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kwong L, Nutescu E. Cost–effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health9(2), 68–76 (2006).
   PubMedGoogle Scholar
• Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am. J. Orthop.32(4), 201–205 (2003).
   PubMedGoogle Scholar
• Wade WE, Spruill WJ, Leslie RB. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery. Am. J. Ther.11(3), 194–198 (2004).
   Google Scholar
• Spruill WJ, Wade WE, Leslie RB. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery. Blood Coagul. Fibrinolysis15(7), 539–543 (2004).
   PubMed Web of Science ®Google Scholar
• Spruill WJ, Wade WE, Leslie RB. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am. J. Ther.11(1), 3–8 (2004).
   PubMedGoogle Scholar
• Lundkvist J, Bergqvist D, Jonsson B. Cost–effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur. J. Health Econ. DOI 10.1007/s10198-006-0017-2 (2007) (Epub ahead of print).
   Google Scholar
• Lundkvist J, Bergqvist D, Jonsson B. Cost–effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur. J. Health Econ.4(4), 254–262 (2003).
   PubMedGoogle Scholar
• Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost–effectiveness analysis. Am. J. Cardiovasc. Drugs5(2), 121–130 (2005).
   PubMedGoogle Scholar
• Dranitsaris G, Kahn SR, Stumpo C et al. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. Am. J. Cardiovasc. Drugs4(5), 325–333 (2004).
   PubMedGoogle Scholar
• Shorr AF, Jackson WL, Moores LK, Warkentin TE. Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. J. Thromb. Thrombolysis23(3), 229–236 (2007).
   PubMedGoogle Scholar
• Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. New anticoagulants: mechanism of action and therapeutic targets. Tunis. Med.83(Suppl. 2), 29–35 (2005).
   Google Scholar
• Lee A, Agnelli G, Buller H et al. Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation104(1), 74–78 (2001).
   PubMed Web of Science ®Google Scholar
• PERSIST Investigators. A novel long-acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis, a Phase II evaluation. Blood100(115) (2002).
   Google Scholar
• Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Haemost.96(3), 274–284 (2006).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Dahl OE et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation114(22), 2374–2381 (2006).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris L, Dahl OE et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost.4(1), 121–128 (2006).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Fisher WD, Bauer KA et al. BAY 59–7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A Phase II dose-ranging study. J. Thromb. Haemost.3(11), 2479–2486 (2005).
   PubMed Web of Science ®Google Scholar
• Agnelli GHS, Krueger KA, Bedding AW, Brandt JT. A Phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood106(11), 278 (2005).
   Google Scholar
• Eriksson BI, Turpie AGG, Lassen MR et al. YM150, an oral direct Factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. ASH Annual Meeting Abstracts106(11), 1865 (2005).
   Google Scholar
• Eriksson BI, Dahl OE, Ahnfelt L et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost.2(9), 1573–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol.45(5), 555–563 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost.3(1), 103–111 (2005).
   PubMed Web of Science ®Google Scholar
• Kearon C, Comp P, Douketis J et al. Dose–response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost.3(5), 962–968 (2005).
   PubMed Web of Science ®Google Scholar